Research progress of traditional Chinese medicine for the invasion and metastasis of hepatocellular carcinoma

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is a common cancer worldwide. Its morbidity and mortality remain significantly high. HCC invasion and metastasis are key factors affecting the efficacy of therapy to patients; they also are the indicators to evaluate the prognosis and survival of patients. Therefore, finding ways to repress HCC invasion and metastasis is a popular area of research. In this article, we introduce how traditional Chinese medicine comprehends the progress of HCC invasion/ metastasis in the aspects of: theory investigation, experimental study, and clinical study, and provide the summary of research progress of traditional Chinese medicine for the invasion and metastasis of hepatocellular carcinoma.

Key words: hepatocellular carcinoma, Chinese medicine, invasion, metastasis

CLC Number:

R735.7

ZHANG Ying, ZHOU Yuanfeng, HU Min. Research progress of traditional Chinese medicine for the invasion and metastasis of hepatocellular carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 594-600.

References

［1］International Agency for Research on Cancer［EB/OL］. Available from: http://www-dep.iarc.fr/
［2］陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡［J］.中国肿瘤,2014,23(1):1-10.
［3］Rebecca L,Siegel MPH, Kimberly D,et al.Cancer Statistics［J］,2016,CA Cancer J Clin,2016:66(1):7-30.
［4］Siegel RL, Miller KD, Jemal A.Cancer statistics［J］.2015,CA Cancer J Clin,2016,66(2):115-132.
［5］Sonia P, Iván H, Javier I. New advances in hepatocellular carcinoma ［J］.Hepatology,2016,8(9):421-438.
［6］Lau WY,Lai EC.Hepatocellular carcinoma:current managementand recent advances［J］.Hepatobiliary Pancreat Dis Int,2008,7(3):237-257.
［7］Korean Liver Cancer Study Group (KLCSG) and National CancerCenter, Korea (NCC).2014 Korean Li-ver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma［J］.Korean J Radiol,2015,16(3):465-522.
［8］Parissa T,Sasan R,Myron ES.Current management of hepatocellular carcinoma［J］. Gastroenterology. 2014, 20(30):10223-10237.
［9］贺珊,廖长秀.基于信号转导通路的中药抗肝癌侵袭转移机制的研究进展［J］.世界华人消化杂志,2016,24(15):2347-2354.
［10］刘雪丽,周学锋,王君瑜,等.中药抗肿瘤作用机制研究进展［J］.中国药师,2016,19(6):1158-1162.
［11］刘平.加强中西医结合防治肝癌的临床研究［J］.临床肝胆病杂志,2016,32(4):615-618.
［12］詹磊.沈忠源理肝抗癌方治疗肝癌的经验［J］.湖北中医杂志,2016,38(3):30-31.
［13］孙晓霞,孟静岩.中医药抗癌转移的研究进展［J］.甘肃中医,2007,20(11):56-57.
［14］贺用和,韩静.论“风”与肿瘤转移［J］.中国中医基础医学杂志,2006,12(2):124-126.
［15］石兆峰,杜永平,谢娟.挖掘“肝癌”在中医古籍中的论治［J］.中西医结合肝病杂志,2016,26(02):122-123+129.
［16］林晓峰,赵永山.运用整体观念治疗恶性肿瘤的思考［J］.中医药学刊,2006,24(11):2072-2073.
［17］王淙悦,喻明,王华伟,等.中药应用于肿瘤转移的20年用药规律探索［J］.环球中医药,2014,7(2):113-116.
［18］李彦博,孙静.益气养阴方对小鼠肝癌实验性转移的影响［J］.中国中医药科技,2009,16(5):349-350,362,336.
［19］高连印,韦艾凌.活血化瘀药调控肝细胞癌微环境细胞因子影响肿瘤转移复发机制初探［J］.环球中医药,2014,7(2):119-121.
［20］Helicia P,Navneeta P,Yang J.Invading one stepat a time: the role of invadopodia in tumor metastasis［J］.Oncogene,2014,33(33):4193-4202.
［21］Deng YR,Liu WB,Lian ZX,et al.Sorafenibinhibits macrophage-mediated epithelial-mesenchymal transi-tion in hepatocellular carcinoma［J］.Oncotarget,2016,7(25):38292-38305.
［22］Jun M,Ken S,Keishi S,et al.Review of angiogenesis in hepatocellular carcinoma［J］.Hepatology Resear-ch,2015,45(1):1-9.
［23］闪海霞,朱幼芙,范崇桂,等.Wnt信号通路对肝细胞肝癌的影响［J］.广东医学,2016,37(4):572-574.
［24］White BD, Chien AJ, Dawson DW.Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers［J］.Gastroenterology,2012,142(2):219-232.
［25］Ben-Neriah Y, Karin M.Inflammation meets cancer,with NF-kappaBas the matchmaker［J］.Nat Immu-nol,2011,12(8):715-723.
［26］Karin M, Cao Y, Greten FR, et al.NF-kappaB in cancer: from innocent bystander to major culprit［J］.Nat RevCancer,2002,2(4):301-310.
［27］杜琴,胡兵,沈克平,等.白藜芦醇联合姜黄素对SMMC-7721肝癌细胞作用［J］.中国实验方剂学杂志,2012,18(9):262-266.
［28］夏鑫华,刘梅.丹参酮Ⅱ_A和丹酚酸B对肝癌HepG_2细胞株的作用及其机制探讨［J］.中药材,2014,37(4):652-655.
［29］何鑫,何剪太,张阳德.人参皂苷Rh_2对人肝癌Bel-7402细胞增殖和凋亡的影响［J］.中国现代医学杂志,2012,22(20):24-27.
［30］黄春,李润琴.苦龙胆脂甙对肝癌细胞增殖、凋亡和迁移的作用［J］.中药药理与临床,2016,32(3):53- 57.
［31］Zhu PP,Yuan SG,Liao Y,et al.High level of intercell-ular adhesion molecule-1 affects prognosis ofpatie-nts with hepatocellularcarcinoma［J］.World J Gastroenterol,2015,21(23):7254-7263.
［32］王金果,刘亚娴.甲乙煎影响H_(22)小鼠肝癌组织黏附分子CD_(54)表达的实验研究［J］.河北中医，2009,31(5):756-758+786+801.
［33］尹天翔,王燕燕.人参皂苷Rg3对人肝癌细胞增殖、迁移、黏附和凋亡的影响及其作用机制［J］.基础医学与临床,2015,35(3):303-307.
［34］陆玲玲.人参皂苷Rg3联合索拉非尼对人肝癌细胞株侵袭与转移的影响［J］.中国老年学杂志,2016,36(5):1067-1069.
［35］贺武斌,苏荣健.白头翁皂苷D联合索拉非尼对人肝癌细胞侵袭与转移的影响［J］.山东大学学报(医学版),2016,54(7):18-22.
［36］Giannelli G,Koudelkova P,Dituri F,etal.Role of epithelial to mesenchymal transition in hepatocellular carcinoma［J］.J hepatol,2016,65(4):708-808.
［37］郭晨旭,吴迎春,朱元章,等.藏族药翼首草正丁醇部位提取物体外抑制人肝癌Hep3B细胞增殖和侵袭转移［J］.中国实验方剂学杂志,2015,21(3):100-105.
［38］钱亚云,金凤,曹玲,等.南蛇藤提取物对人肝癌细胞HepG2上皮间质转化的影响［J］.世界科学技术中医药现代化,2014,16(12):2647-2651.
［39］张军,杨祖奎.基质金属蛋白酶和肝癌的侵袭转移［J］.中华肝胆外科杂志,2004,10(10):718-720.
［40］李学农,庄将协.β-榄香烯对人肝癌细胞侵袭转移及相关机制的实验研究［J］.福建医药杂志,2012,34 (3):70-73.
［41］余丽芳,饶智国,章必成,等.桑白皮提取物对HepG2细胞增殖和迁移的抑制作用［J］.华南国防医学杂志,2014,28(11):1057-1060.
［42］蔡岳,王晓东,张赤志,等.皂荚提取物对肝癌大鼠基质金属蛋白酶抑制因子3/基质金属蛋白酶蛋白的影响［J］.中西医结合肝病杂志,2015,25(4):224-226+258.
［43］Wang WZ,LiL,LiuMY,et al.Curcumin induces Fas L-related apoptosis through p38 activation in human hepatocellular carcinoma Huh7 cells［J］.Life Sci,2013,92(6/7):352-358.
［44］李会宣,杨虹,张红兵,等.姜黄素通过MAPK信号通路诱导人肝癌SMMC-7721细胞凋亡［J］.天然产物研究与开发,2014,26(3):329-334.
［45］陈永安,程蕾,苗洁琼,等.雷公藤甲素抑制人肝癌MHCC97H细胞侵袭转移的实验研究［J］.福建中医药大学学报,2012,22(2):22-24.
［46］冯子强,左国伟,石庆强,等.人参皂苷Rh2抑制肝癌HepG2细胞迁移的实验研究［J］.中国免疫学杂志,2015,31(1):61-65.
［47］Liao JC,Lee KT,Yo uBJ,et al.Raf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migration［J］.Food Nutr Res,2015,59:29884.
［48］Bryan DW,Andy JC,David WD.Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers［J］. Gastroenterology,2012,142(2):219-232.
［49］赵琳琳,陈剑群,徐学军.姜黄素对肝癌细胞Bel7402、QGY7703增殖凋亡及Wnt/β-catenin信号通路的影响［J］.中华临床医师杂志(电子版),2013,7(11):4902-4906.
［50］Gai JQ, Sheng X,Qin JM,et al.The effect and mechanism of bufalin on regulating hepatocellularcarcin-macell invasion and metastasis via Wnt/β-catenin signaling pathway［J］.Int J Oncol,2016,48(1):338-348.
［51］孙海涛,贺松其,文彬,等.鳖甲煎丸对肝癌细胞中Wnt信号分子β-catenin、GSK-3β及靶基因CD44v6、VEGF的影响［J］.南方医科大学学报,2014,34(10):1454-1458.
［52］董云巧,马文丽,顾金保,等.华蟾素注射液对HepG2细胞NF-κB通路的影响［J］.南方医科大学学报， 2010,30(1):137-139,142.
［53］Hu B, Sun D, Sun C,et al. A polymeric nanoparticle formulation ofcurcumin in combination withsorafe-nibsynergistically inhibits tumor growth and metastasis in an orthotopicmodel of human hepatocellular carcinoma［J］.BiochemBiophys Res Commun,2015,468(4):525-532.
［54］任为,牟宜双,许可,等.迷迭香酸通过诱导凋亡及抑制NF-κB信号通路发挥抗肝癌作用的机制研究［J］.中药药理与临床,2016,32(2):31-35.
［55］任牡丹,胡雅楠,和水祥,等.丹参酮ⅡA对人肝癌细胞Ang-2及其受体Tie-2表达的影响［J］.西安交通大学学报(医学版),2012,33(2):203-206,210.
［56］史国军,山广志,邱慧颖.健脾柔肝方含药血清诱导人肝癌细胞SMMC-7721凋亡及对VEGF表达的影响［J］.中华中医药学刊,2016,34(3):654-656.
［57］史国军,山广志,邱慧颖.健脾柔肝汤对肝癌小鼠癌组织VEGF及MVD表达影响的研究［J］.中国中医药科技,2014,21(6):627-629.
［58］王雅楠,曹蕊,朱聪,等.夏枯草硫酸多糖对肝癌血管生成的作用及机制研究［J］.中国肿瘤临床,2014,41 (12):758-761.
［59］高立生,刘宁宁,邵雪斋.肿瘤对机体免疫功能影响的研究进展［J］.河北医学,2008,14(9):1101-1104.
［60］王前程,陈炜,陈大庆,等.动脉灌注蟾酥、丹参、苦参碱联合TACE对肝癌患者免疫功能的影响［J］.胃肠病学和肝病学杂志,2013,22(7):632-634.
［61］李颖,赵兴敏,徐洪亮,等.康莱特注射液配合化疗对肝癌的治疗效果及免疫细胞活性的影响［J］.现代生物医学进展,2014,14(11):2103-2106.
［62］高丽君,万幸,潘华新,等.去甲斑蝥素联合环磷酰胺对H22荷瘤小鼠免疫功能的影响［J］.中国中医药咨讯,2011,3(3):150-151.
［63］王永中,姚树坤,高立明,等.清肝化瘀口服液对原发性肝癌介入治疗后免疫功能影响的临床研究［J］.中国老年学杂志,2008,28(8):770-772.
［64］Borsi E,Terragna C,Brioli A,et al.Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma［J］.Transl Res,2015,65(6):641-650.
［65］Xu LF, Ni JY, Sun HL, et al.Effects of hypoxia-inducible factor-1α silencingon the proliferation of CBRH-7919 hepatomacells［J］.World J Gastroenterol,2013,19(11):1749-1759.
［66］宋长城,吕祥,程彬彬,等.蜂毒素对人肝癌裸鼠移植瘤的抗血管生成作用［J］.实用癌症杂志,2011,26 (6):551-554.
［67］周薇,戴奇刚,邓鑫,等.EGCG对人肝癌SMMC-7721细胞增殖抑制作用及对缺氧反应的影响［J］.中国医药指南,2013,11(15):92-95.
［68］谢永财,王海生,张谷风.丹参对肝癌大鼠模型缺氧诱导因子-1α及微血管密度的影响［J］.福建中医药大学学报,2012,22(3):14-17.
［69］吴婷婷,吴伟忠,高东梅,等.补肾健脾方抑制裸鼠高转移原位肝癌切除术后肿瘤复发以及对索拉非尼的增效减毒作用［J］.上海中医药杂志,2015,49(9):63-66,76.
［70］李晓娟,郭晓东,白云峰,等.扶正化积方对H22肝癌荷瘤小鼠化疗的增效减毒作用［J］.现代生物医学进展,2015,15(31):6024-6026,6020.
［71］廖作庄,韦丽美,徐灵源,等.白花蛇舌草注射液逆转人肝癌细胞BEL-7402/5-FU的多药耐药作用［J］. 西安交通大学学报(医学版),2015,36(4):554-557.
［72］白广德,练祖平,黄丁平,等.中西医结合防治中晚期肝癌复发转移的临床研究［J］.吉林中医药,2010,30 (8):674-675.
［73］钟崇,李惠东,陈智远,等.健脾化瘀中药治疗肝癌临床研究［J］.新中医,2013,45(12):129-132.
［74］王永中.清肝化瘀口服液对介入治疗后肝癌患者的临床疗效［J］.中国实验方剂学杂志,2011,17(8):259-261.

[1]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[2]	HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie. Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
[3]	QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
[4]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[5]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[6]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[7]	QI Xiaofeng, LUO Yali, XIAO Mengyong, ZHOU Shiqin, ZHOU Wen, AN Fangyu, WEI Benjun, LIU Yongqi. Research status of dialectical prevention and treatment of acute lung injury based on the theory of "Wei qi and Ying Xue" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 429-437.
[8]	WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei. Mechanism of DCLK1 transcriptional regulation in HCC [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
[9]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[10]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[11]	SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui. Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.
[12]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[13]	YE Xiaodi, MIAO Yunping, CHEN Aiying, CHENG Min, TIAN Xuejun, ZHENG Gaoli . Optimization and verification of orthotopic non-muscle invasive bladder cancer model in nude mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 473-480.
[14]	CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
[15]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.